EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and Indonesia

Liony Fransisca, Maria Ome-Kaius, Moses Laman, Jeanne Rini Poespoprodjo, Ayodhia P Pasaribu, Inge Sutanto, Mary Malai, Erni Nelwan, Jacklyn Adella, Cynthia Abegini, Framita Ainur, Yolyne Amdara und 37 weitere

The Lancet Regional Health - Western Pacific · 2026-06 · 71 · 101903

DOI: 10.1016/j.lanwpc.2026.101903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2026-06. Verfasst von Liony Fransisca und 48 weiteren Autor:innen. Beteiligte Einrichtung: Yayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unitaid, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High total dose primaquine (PQ 7 mg/kg) over 7 days can improve treatment adherence and reduce Plasmodium vivax malaria recurrences. We evaluated the safety of pre-treatment glucose-6-phosphate dehydrogenase (G6PD) testing followed by high-dose primaquine for P. vivax malaria in Indonesia and Papua New Guinea.

Methods

Patients with P. vivax malaria presenting to four community health clinics were screened for G6PD deficiency using the STANDARD G6PD (SD Biosensor, Republic of Korea) and treated with PQ7 (1 mg/kg/day, 7 days) if G6PD normal, PQ14 (0.5 mg/kg/day, 14 days) if G6PD intermediate, and PQ8W (0.75 mg/kg/week, 8 weeks) if G6PD deficient. Safety and tolerability were assessed through community-based follow-up by study teams on days 3 and 7.

Findings

Between October 2023 and September 2024, 800 patients were enrolled: 626 (78.3%) received PQ7, 148 (18.5%) PQ14, and 26 (3.3%) PQ8W. Of those patients who did not withdraw, 97.8% (773/790) were followed up on day 3 and 97.7% (765/783) on day 7. A total of 27 adverse events of special interest (AESIs) were reported in 26 patients; the risk of an AESI was 2.7% (17/626) of patients treated with PQ7, 4.1% (6/148) of patients treated with PQ14 and 11.5% (3/26) of patients treated with PQ8W. Overall, 24 AESIs (88.9%) were related to haemolysis, with the majority (n = 21) due to a fall in haemoglobin >3 g/dL, all without clinical compromise. Serious adverse events (SAEs) occurred in 16 (2.0%) patients, mostly gastrointestinal intolerance (68.8%; 11/16) in patients receiving PQ7. Of the 626 patients treated with PQ7, 9 (1.4%) experienced SAEs that were probably or possibly related to primaquine.

Interpretation

The implementation of G6PD testing to guide primaquine treatment of patients with P. vivax malaria was feasible and the primaquine regimens had acceptable safety profiles. The study paves the way for large scale implementation studies of the intervention. Funding: UNITAID and Australian National Health and Medical Research Council.

Schlagwörter

Stichwörter der Autor:innen

G6PD testingPharmacovigilancePlasmodium vivaxPrimaquineRadical cure

Autor:innen und Institutionen

  • Yayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia.
  • Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
  • Papua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
  • Centre for Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Department of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
  • Tridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia.

Förderung

  • Unitaid
  • National Health and Medical Research Council

Zitieren

APA

Fransisca, L., Ome-Kaius, M., Laman, M., Poespoprodjo, J. R., Pasaribu, A. P., Sutanto, I., Malai, M., Nelwan, E., Adella, J., Abegini, C., Ainur, F., Amdara, Y., Angeline, S., Brown, K., Burdam, F. H., Curry, E., Daimen, M., Daly, P., Do, T., …, & Price, R. N. (2026). High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and Indonesia. The Lancet Regional Health - Western Pacific, 71, 101903. https://doi.org/10.1016/j.lanwpc.2026.101903

Vancouver

Fransisca L, Ome-Kaius M, Laman M, Poespoprodjo JR, Pasaribu AP, Sutanto I, et al. High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and Indonesia. The Lancet Regional Health - Western Pacific. 2026;71:101903. doi:10.1016/j.lanwpc.2026.101903

BibTeX
@article{Fransisca2026,
  author = {Fransisca, Liony and Ome-Kaius, Maria and Laman, Moses and Poespoprodjo, Jeanne Rini and Pasaribu, Ayodhia P and Sutanto, Inge and Malai, Mary and Nelwan, Erni and Adella, Jacklyn and Abegini, Cynthia and Ainur, Framita and Amdara, Yolyne and Angeline, Sherley and Brown, Katelyn and Burdam, Faustina H and Curry, Ella and Daimen, Martin and Daly, Paul and Do, Thy and Dori, Annie and Douglas, Nicholas M and Huegel, Heike and Hutagalung, Azkarunia P and Jambert, Elodie and Jimanto, Vincent and Karo, Vali and Kenangalem, Enny and Kelebi, Trevor and Kisomb, Jacob and Laksono, Ida and Lee, Grant and Ley, Benedikt and Mannion, Kylie and Plinduo, Julius and Pukai, Irene and Putri, Adela and Rajasekhar, Megha and Ronkentou, Sharol and Rosens, Evelien and Sakalidis, Vanessa S and Satyagraha, Ari and Simpson, Julie A and Theodora, Minerva and Ubra, Reynold and Vakore, Norman and Wansom, Tanyaporn and Duparc, Stephan and Robinson, Leanne J and Price, Ric N},
  title = {High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and Indonesia},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2026},
  volume = {71},
  pages = {101903},
  doi = {10.1016/j.lanwpc.2026.101903}
}
Kostenlos starten →